Twelve percent of your body weight, gone in 36 weeks, from a pill you can swallow with breakfast or without it. That’s the headline number out of a randomized phase II trial of aleniglipron published in Nature Medicine, and the pill part matters as much as the percentage.
Every GLP-1 drug that’s had a cultural moment so far comes with a needle. Semaglutide, sold as Ozempic and Wegovy, is a peptide. Peptides get injected. Aleniglipron isn’t a peptide at all.
Why a small molecule changes the math
Aleniglipron is a small-molecule drug, chemically synthesized rather than grown, and it’s being developed as an obesity treatment you take by mouth. That single structural difference cascades into everything patients complain about with the current generation.
Injectable GLP-1s can work extremely well. Getting them is another story. They need refrigeration, they need needles, and they’re hard and expensive to manufacture at the volume demand actually requires.
Small-molecule versions could sidestep some of that, said Robert Kushner, MD, ’82 GME, professor emeritus of Medicine in the Division of Endocrinology, Metabolism and Molecular Medicine at Northwestern and a co-author of the study. They’re oral, and they may be easier to produce in bulk.
“The difference with aleniglipron is it’s a small molecule, which means it’s chemically made and could be taken with or without food. Most medications we take, whether it’s aspirin or blood pressure medicine, are small molecules. They’re chemicals that you make structurally, and because of that you can potentially combine them with other medications,” Kushner said.
That last clause is the part worth circling. Combination therapy is a lot easier to design around a chemical than around a refrigerated peptide.
What 230 adults actually did for 36 weeks
The trial was placebo-controlled and double-blind, run across 38 U.S. medical centers, with 230 adults who had obesity or overweight. Average age was 50.
Participants were randomized into three dose groups: 45, 90 or 120 milligrams. One oral dose a day, with the dose stepped up every four weeks, or placebo. Thirty-six weeks total.
The dose-response curve did what you’d want it to do. Average body-weight change from baseline landed at -9.0 percent at 45 milligrams, -10.7 percent at 90 milligrams and -12.1 percent at 120 milligrams. Placebo moved -0.5 percent.
The side effects nobody’s surprised by
Gastrointestinal problems showed up, because they always do with this drug class. They were generally mild to moderate across the treatment groups, and they got less frequent as the study went on.
Discontinuation ran to 10.4 percent of participants overall. Researchers reported no cases of drug-induced liver injury, which is a specific thing to check for and a specific thing to have found nothing of.
Kushner said the findings support pushing alenglipron forward as an obesity treatment and testing how well it works in an upcoming phase III trial.
“We didn’t find any concerns; no new safety signals. We found a dose that seems to be effective, and the dose escalation will be slowed down further as we go into phase III trial to increase tolerability,” Kushner said.
Read that carefully. Slowing the escalation in phase III is an admission that ramping to 120 milligrams on a four-week ladder was rougher than they’d like, even with side effects tapering off over time.
What this is and isn’t
This is a phase II safety trial in 230 people, not a head-to-head against semaglutide, and nobody has run that comparison here. The work was supported by Structure Therapeutics.
The number to watch in phase III isn’t the weight loss percentage. It’s whether a gentler dose ramp can hold that -12.1 percent while pulling the 10.4 percent dropout rate down, because a pill people quit taking is worth less than a shot they don’t.
